APGE Apogee Therapeutics, Inc. Common Stock

$36.90

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/18/2025

About Apogee Therapeutics, Inc. Common Stock

Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company is headquartered in Waltham, Massachusetts.

Website: https://www.apogeetherapeutics.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1974640
Address
221 CRESCENT ST., BUILDING 17, WALTHAM, MA, UNITED STATES
Valuation
Market Cap
$1.92B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
2.68
Performance
EPS
$-3.30
Dividend Yield
—
Profit Margin
0.00%
ROE
-33.20%
Technicals
50D MA
$35.67
200D MA
$45.19
52W High
$63.50
52W Low
$26.20
Fundamentals
Shares Outstanding
45M
Target Price
$93.88
Beta
nan

APGE EPS Estimates vs Actual

● Estimated
● Actual

APGE News & Sentiment

Aug 11, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis ...
Aug 06, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. ( APGE ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 152.4% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Jul 08, 2025 • Benzinga SOMEWHAT-BULLISH
Gold Falls 1%; ProKidney Shares Spike Higher - Apogee Therapeutics ( NASDAQ:APGE ) , Blue Gold ( NASDAQ:BGL )
U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping more than 150 points on Tuesday. The Dow traded down 0.35% to 44,249.09 while the NASDAQ gained 0.07% to 20,427.63. The S&P 500 also fell, dropping, 0.03% to 6,228.39. Energy shares jumped by 2.1% on Tuesday.
Jul 07, 2025 • Benzinga SOMEWHAT-BULLISH
Dow Dips 1%; Mustang Bio Shares Spike Higher - Apogee Therapeutics ( NASDAQ:APGE ) , Artelo Biosciences ( NASDAQ:ARTL )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Monday. The Dow traded down 1% to 44,379.69 while the NASDAQ declined 0.85% to 20,426.99. The S&P 500 also fell, dropping, 0.39% to 6,255.16. Industrials shares jumped by 0.1% on Monday.
Jul 07, 2025 • Benzinga SOMEWHAT-BULLISH
Top 2 Health Care Stocks That May Plunge This Month - Apogee Therapeutics ( NASDAQ:APGE ) , Phibro Animal Health ( NASDAQ:PAHC )
As of July 7, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
Jul 07, 2025 • Benzinga NEUTRAL
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial - Apogee Therapeutics ( NASDAQ:APGE )
APG777 cut eczema severity by 71% at Week 16 vs. 33.8% for placebo; 66.9% reached EASI-75. Itch severity reduced by 50.7% within one week; APG777 was well tolerated with no safety concerns raised. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July.
Sentiment Snapshot

Average Sentiment Score:

0.244
50 articles with scored sentiment

Overall Sentiment:

Bullish

APGE Reported Earnings

Mar 11, 2025
Dec 31, 2024 (Pre market)
-0.13 Surprise
  • Reported EPS: $-1.20
  • Estimate: $-1.07
  • Whisper: —
  • Surprise %: -11.9%
Nov 13, 2024
Sep 30, 2024 (Pre market)
-0.12 Surprise
  • Reported EPS: $-0.86
  • Estimate: $-0.74
  • Whisper: —
  • Surprise %: -16.2%
Aug 26, 2024
Jun 30, 2024 (Pre market)
-0.05 Surprise
  • Reported EPS: $-0.60
  • Estimate: $-0.55
  • Whisper: —
  • Surprise %: -9.1%
May 13, 2024
Mar 31, 2024 (Pre market)
-0.03 Surprise
  • Reported EPS: $-0.64
  • Estimate: $-0.61
  • Whisper: —
  • Surprise %: -4.9%
Mar 05, 2024
Dec 31, 2023 (Pre market)
0.17 Surprise
  • Reported EPS: $-0.32
  • Estimate: $-0.49
  • Whisper: —
  • Surprise %: 34.7%
Nov 13, 2023
Sep 30, 2023 (Pre market)
-0.1 Surprise
  • Reported EPS: $-0.51
  • Estimate: $-0.41
  • Whisper: —
  • Surprise %: -24.4%
Aug 28, 2023
Jun 30, 2023 (Pre market)
-2.08 Surprise
  • Reported EPS: $-3.78
  • Estimate: $-1.70
  • Whisper: —
  • Surprise %: -122.3%
May 31, 2023
Mar 31, 2023 (Pre market)
-2.38 Surprise
  • Reported EPS: $-2.38
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%

Financials